.After raising $170 million back in February, metabolic disease-focused BioAge Labs has actually filed to debut on the public market.The Eli Lilly-partnered biotech expect to provide on the Nasdaq under the symbol "BIOA," according to documents filed with the Securities and also Substitution Payment. The company has certainly not openly shared an expected financial amount for the offering.The clinical-stage firm touts lead candidate azelaprag, an orally delivered little molecule slated to go into phase 2 testing in combo with semaglutide-- marketed by Novo Nordisk under trademark name Wegovy for fat burning-- in the first half of next year. Semaglutide is actually also offered as Ozempic and Rybelsus by Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is actually created to mix properly along with GLP-1 medicines, enhancing weight management while preserving muscular tissue mass. The investigational medicine was found to become well-tolerated one of 265 people around 8 stage 1 trials, according to BioAge.Earlier, BioAge amassed the assistance of Lilly to manage a trial combining azelaprag along with the Significant Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetes mellitus as Mounjaro and also Zepbound for weight loss. The partners are presently conducting a phase 2 trial of azelaprag and tirzepatide, along with topline results anticipated in the 3rd one-fourth of 2025.The biotech is actually also planning a the hormone insulin level of sensitivity proof-of-concept test evaluating azelaprag as a monotherapy in the 1st half of upcoming year to assist potential evidence growth. Moreover, the company intends to inquire the FDA for authorization in the 2nd half of 2025 to release human testing for an NLRP3 inhibitor targeting metabolic diseases and neuroinflammation.BioAge's anticipated transfer to the public market complies with a light uptick in organized biotech IPOs coming from Bicara Rehabs as well as Zenas Biopharma. Zooming out, the recent IPO garden is actually a "combined picture," along with top notch providers still debuting on the public markets, merely in decreased varieties, according to PitchBook.